1. Immunoinformatics mapping of potential epitopes in SARS-CoV-2 structural proteins
- Author
-
Chongtham Shyamsunder Singh, Ramesh C. Deka, Suvendra Kumar Ray, Aditya Kumar, Siddhartha Shankar Satapathy, Partha Pratim Borah, Sushmita Konwar, Manabendra Mandal, Chandrima Doley, Anutee Dolley, Dikshita Dowerah, Nima D. Namsa, Chen Chongtham, Arpita Devi, Latonglila Jamir, Yengkhom Damayanti Devi, Vashkar Biswa, Pabitra Nath, Himanshu Ballav Goswami, Sandeep Das, and Robin Doley
- Subjects
Models, Molecular ,RNA viruses ,Viral Diseases ,B Cells ,Protein Conformation ,Physiology ,Coronaviruses ,Epitopes, T-Lymphocyte ,Biochemistry ,Epitope ,Serology ,White Blood Cells ,Medical Conditions ,Animal Cells ,Immune Physiology ,Medicine and Health Sciences ,Public and Occupational Health ,Pathology and laboratory medicine ,Multidisciplinary ,Immune System Proteins ,T Cells ,Medical microbiology ,Vaccination and Immunization ,Infectious Diseases ,Databases as Topic ,Viruses ,Epitopes, B-Lymphocyte ,Medicine ,Structural Proteins ,SARS CoV 2 ,Pathogens ,Cellular Types ,Antibody detection ,Research Article ,COVID-19 Vaccines ,Coronavirus disease 2019 (COVID-19) ,SARS coronavirus ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,Immune Cells ,Science ,Immunology ,Computational biology ,Biology ,Microbiology ,Immune system ,Antigen ,Vaccine Development ,Humans ,Amino Acid Sequence ,Antigens ,Antibody-Producing Cells ,Viral Structural Proteins ,Blood Cells ,SARS-CoV-2 ,Histocompatibility Antigens Class I ,Organisms ,Viral pathogens ,Computational Biology ,Reproducibility of Results ,Biology and Life Sciences ,Proteins ,Covid 19 ,Cell Biology ,Microbial pathogens ,Epitope mapping ,Preventive Medicine ,Epitope Mapping - Abstract
All approved coronavirus disease 2019 (COVID-19) vaccines in current use are safe, effective, and reduce the risk of severe illness. Although data on the immunological presentation of patients with COVID-19 is limited, increasing experimental evidence supports the significant contribution of B and T cells towards the resolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Despite the availability of several COVID-19 vaccines with high efficacy, more effective vaccines are still needed to protect against the new variants of SARS-CoV-2. Employing a comprehensive immunoinformatic prediction algorithm and leveraging the genetic closeness with SARS-CoV, we have predicted potential immune epitopes in the structural proteins of SARS-CoV-2. The S and N proteins of SARS-CoV-2 and SARS-CoVs are main targets of antibody detection and have motivated us to design four multi-epitope vaccines which were based on our predicted B- and T-cell epitopes of SARS-CoV-2 structural proteins. The cardinal epitopes selected for the vaccine constructs are predicted to possess antigenic, non-allergenic, and cytokine-inducing properties. Additionally, some of the predicted epitopes have been experimentally validated in published papers. Furthermore, we used the C-ImmSim server to predict effective immune responses induced by the epitope-based vaccines. Taken together, the immune epitopes predicted in this study provide a platform for future experimental validations which may facilitate the development of effective vaccine candidates and epitope-based serological diagnostic assays.
- Published
- 2021